Millennium Management’s LakeShore Biopharma LSB Stock Holding History

Millennium Management’s Portfolio LSB Stock Details LSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,309	Closed	-$37K	–	6786
2023 Q1	$37K	Buy	+2,309	New	+$117K	﹤0.01%	5719

Other funds holding LSB

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

VAM

Valliance Asset Management Central, Hong Kong $122M AUM 362.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

SLM

Snow Lake Management Menlo Park, California $90.7M AUM 72.65% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

FSI

Flow State Investments Chicago, Illinois $245M AUM 5.06% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Millennium Management's LSB Position: Q2 2023 in Review

Millennium Management sold out of LakeShore Biopharma (LSB) in Q2 2023, closing a stake of 2,309 shares — an estimated $37K sold.

Millennium Management first reported a position in LSB in Q1 2023 and held it in 1 quarter. The position peaked at $37K in Q1 2023. 16 funds tracked by Wall St. Rank hold LSB as of Q2 2023.

Millennium Management reported no remaining LakeShore Biopharma position as of Q2 2023 after selling out during the quarter.
Millennium Management sold 2,309 LakeShore Biopharma shares in Q2 2023, an estimated $37K.
Millennium Management first reported a position in LakeShore Biopharma in Q1 2023 and held it in 1 quarter.
Millennium Management's LakeShore Biopharma position peaked at $37K in Q1 2023.
16 funds tracked by Wall St. Rank held LakeShore Biopharma as of Q2 2023.

Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.